Synlogic Inc. (SYBX) PT Lowered to $13 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
Synlogic Inc. (SYBX) PT Lowered to $14 at Wedbush
August 21, 2019 4:16 AM EDTWedbush analyst David Nierengarten lowered the price target on Synlogic Inc. (NASDAQ: SYBX) to $14.00 (from $20.00) while maintaining a Outperform rating.
... MoreSynlogic Inc. (SYBX) PT Lowered to $6 at Jefferies
August 21, 2019 4:16 AM EDTJefferies analyst Chris Howerton lowered the price target on Synlogic Inc. (NASDAQ: SYBX) to $6.00 (from $18.00) while maintaining a Buy rating.
The analyst comments "After failing to show the efficacy of '1020 in patients, SYBX announced today that it will discontinue... More
Citi Double Downgrades Synlogic Inc. (SYBX) to Sell
August 21, 2019 4:15 AM EDTCiti analyst Yigal Nochomovitz downgraded Synlogic Inc. (NASDAQ: SYBX) from Buy to Sell with a price target of $2.00 (from $20.00).
Says SYNB1020 failure yields little confidence in Synthetic Biotic Platform.Removes product revenues from model for SYNB1020 and... MoreOppenheimer Downgrades Synlogic Inc. (SYBX) to Perform
August 20, 2019 4:07 PM EDTOppenheimer analyst Mark Breidenbach downgraded Synlogic Inc. (NASDAQ: SYBX) from Outperform to Perform.
The analyst comments "Tuesday, Synlogic announced interim results from a Phase 1b/2a trial of SYNB1020 in patients with elevated ammonia. While SYNB1020 showed biomarker-based evidence of ammonia turnover, no... More
Synlogic Inc. (SYBX) PT Lowered to $10 at Piper Jaffray
August 20, 2019 10:24 AM EDTPiper Jaffray analyst Edward Tenthoff lowered the price target on Synlogic Inc. (NASDAQ: SYBX) to $10.00 (from $20.00) while maintaining a Overweight rating.
... MoreUPDATE: Synlogic Inc. (SYBX) PT Lowered to $9.50 at Chardan
August 20, 2019 9:52 AM EDT(Updated - August 20, 2019 9:53 AM EDT)
(update corrects broker)
Chardan analyst Taylor Feehley lowered the price target on Synlogic Inc. (NASDAQ: SYBX) to $9.50 (from $25.00) while maintaining a Buy rating after the company announced the discontinuation of SYNB1020.
... MorePre-Open Movers 08/20: (HGV) (JCP) (BIDU) Higher; (SYBX) (SRPT) (FN) Lower (more...)
August 20, 2019 9:16 AM EDTToday's Pre-Open Movers
Synlogic (NASDAQ: SYBX) 21% LOWER; announced that it is discontinuing development of SYNB1020, an early stage clinical product candidate for the treatment of hyperammonemia. The decision to discontinue the program was based on top-line data from an interim analysis of a randomized, double-blind, placebo-controlled Phase 1b/2a study of the Synthetic Biotic medicine in 23 patients with cirrhosis and elevated blood ammonia. The study was designed to evaluate the safety and tolerability of SYNB1020 treatment, as well as changes in blood ammonia levels and several exploratory endpoints... More
Synlogic (SYBX) Discontinuing Development of SYNB102
August 20, 2019 9:04 AM EDTSynlogic, Inc., (Nasdaq: SYBX) announced that it is discontinuing development of SYNB1020, an early stage clinical... More
